Immix Biopharma, Inc. (NASDAQ:IMMX) Sees Significant Drop in Short Interest

Immix Biopharma, Inc. (NASDAQ:IMMX) was the target of a significant decrease in short interest in December. As of December 31st, there was short interest totalling 356,500 shares, a decrease of 11.0% from the December 15th total of 400,500 shares. Approximately 2.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 165,700 shares, the days-to-cover ratio is presently 2.2 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Immix Biopharma in a research report on Monday, January 6th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC increased its holdings in shares of Immix Biopharma by 5.6% during the 3rd quarter. Geode Capital Management LLC now owns 150,082 shares of the company’s stock worth $224,000 after buying an additional 7,954 shares during the last quarter. Invst LLC acquired a new stake in Immix Biopharma during the second quarter worth $57,000. Finally, FNY Investment Advisers LLC purchased a new stake in Immix Biopharma in the fourth quarter valued at $63,000. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Stock Down 1.0 %

IMMX traded down $0.02 during trading on Friday, reaching $2.04. The company’s stock had a trading volume of 121,030 shares, compared to its average volume of 140,296. The firm has a fifty day simple moving average of $2.07 and a two-hundred day simple moving average of $1.95. The company has a market cap of $56.12 million, a price-to-earnings ratio of -2.40 and a beta of 0.27. Immix Biopharma has a 1 year low of $1.26 and a 1 year high of $5.73.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08). As a group, equities analysts forecast that Immix Biopharma will post -0.74 EPS for the current fiscal year.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.